Actively Recruiting
Randomized Study Evaluating Oral Zelicapavir Compared to Placebo for High-Risk Adults with RSV Infection
Led by Enanta Pharmaceuticals, Inc · Updated on 2026-11-02
860
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating zelicapavir, a new oral drug that blocks RSV replication, in adults who are at high risk for severe respiratory syncytial virus RSV infection. This phase 2b3 randomized, double-blind, placebo-controlled study focuses on adults aged 75 and older or those aged 18 and over with chronic obstructive pulmonary disease COPD or congestive heart failure CHF. Participants are non-hospitalized adults with RSV symptoms for up to 72 hours who test positive for RSV. Participants will be randomly assigned to receive either 800 mg of zelicapavir or a matching placebo, both taken orally once daily for 7 days. The study compares the effects of the investigational drug versus placebo during this treatment period. The primary goal is to assess how quickly participants recover from RSV symptoms, with various secondary measures including hospitalization rates, symptom resolution, viral load changes, and safety evaluations. Throughout the study, participants will be monitored for symptom improvement using the Respiratory Infection Intensity and Impact Questionnaire RiiQ and other scales from Day 1 to Day 35. Researchers will track hospitalizations, deaths, medical visits, and viral load changes. Plasma levels of zelicapavir will be checked on Day 7. Safety is closely followed by recording adverse events during the 35-day observation period. The total participation lasts several weeks, with multiple assessments to understand treatment effects and safety.
CONDITIONS
Brief Title
A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease
Research Team
C
Chris Harris, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here